A new pharmaceutically acceptable salt of hydroxysafflor yellow A as presented in formula (I), in particular new monomer compounds of potassium, ammonium, calcium, and magnesium salts of hydroxysafflor yellow A, preparation method therefor, and medical uses thereof are provided. Compared to hydroxysafflor yellow A, the hydroxysafflor yellow A pharmaceutical salts of the present invention have a purity of at least 98% and are monomer compounds that are safer, more effective, stable, and controllable. The salts have the effects against PAF- or ADP-induced platelet aggregation, and can be used in treating blood circulatory disorders such as platelet aggregation, coronary artery diseases, angina, and acute cerebral ischemia to the effect comparable to hydroxysafflor yellow A, wherein, n and M are defined as in the description.
